Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

NCT02879994 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

11

Enrollment

OTHER

Sponsor class

Conditions

Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Pembrolizumab

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]